The NTAGI has not yet suggested any change in the schedule of Bharat Biotech's Covaxin.
'The real story of 2025 is that India officially stopped being a 'market of the future' and started acting as the world's primary economic engine.'
Actor Poonam Pandey is not being considered as the brand ambassador of the government's national campaign to spread awareness on cervical cancer, Union health ministry officials said on Wednesday.
The Union health ministry has reduced the gap between the second and precaution dose of COVID-19 vaccine for all beneficiaries from nine to six months following a recommendation by National Technical Advisory Group on Immunisation (NTAGI).
According to officials, an additional dose of vaccine is different from a booster dose.
These decisions were taken by the ministry based on the fresh recommendations by The National Expert Group on Vaccine Administration for COVID-19 (NEGVAC) and have also been communicated to the states and union territories, an official statement said.
Of the estimated 7.4 crore (7,40,57,000) population in the 15-18 age bracket, over 3.45 crore have received the first dose of Covaxin so far and their second dose is due in 28 days, he said.
The gap between second dose of COVID-19 vaccine and the third, which is being called a 'precaution dose,' is likely to be nine to 12 months, official sources said on Sunday.
The minister will review the COVID-19 situation at 11:30 am on Wednesday 'considering the international scenario', they said.
The NTAGI has recommended that those who need to travel overseas can take the precaution dose of Covid vaccine as required by the country they are travelling to, before the stipulated nine-month waiting period, sources told PTI.
The Union health ministry on Wednesday dismissed media reports claiming there was dissent from technical experts about increasing the gap between two Covishield doses and said the decision was based on scientific reason about the behaviour of adenovector vaccines.
The government is likely to soon reduce the gap between the second dose of Covid-19 vaccine and the precaution dose from the current nine months to six months, official sources said on Wednesday.
Under the National COVID-19 Vaccination Programme, more than 148 crore vaccine doses have been successfully administered.
The Standing Technical Sub-Committee (STSC) of the National Technical Advisory Group on Immunisation (NTAGI) on Thursday recommended reducing the gap between the second and precaution doses of COVID-19 vaccines from the current nine to six months, official sources said.
This decision of revised time interval between two doses is applicable only to Covishield and not to Covaxin vaccine, the ministry said.
The government on Friday said 25 cases of the Omicron variant of the coronavirus have been detected in India so far and that mostly mild symptoms have been noted in all the cases.
Zydus Cadila has agreed to bring down the price of its COVID-19 vaccine to Rs 265 a dose following persistent negotiations by the government but a final deal is yet to be reached, sources said on Sunday.
In the major Indian cities, the Omicron variant of the coronavirus is accounting for more than 50 per cent of the fresh cases of the infection and the massive surge in the number of cases over the last one week is indicative of a third wave of the pandemic, as is being witnessed in several countries, Dr N K Arora, chairman of the COVID-19 working group of the NTAGI, said on Tuesday.
Union Health Minister Mansukh Mandaviya on Tuesday told Bharatiya Janata Party MPs that Covid vaccination for children is likely to start soon, sources said.
There is no scientific evidence so far to support the need for a booster vaccine dose against COVID-19, ICMR Director General Dr Balram Bhargava said on Monday underlining the completion of second dose for India's adult population is the priority for the government for now.
'The protective effect of the vaccine lasts for about nine months to a year.' 'For health workers that period is already over. This is the right time to augment their immunity.'
With talks underway between the central government and Zydus Cadila over the pricing of the COVID-19 vaccine ZyCov-D, the pharma company is learnt to have proposed a price of Rs 1,900 for its three-dose jab that can be given to those above 12 years of age.
'The key purpose of vaccination is to prevent hospitalisation, severe disease, and death.' 'All vaccines work equally, although mild disease cannot be prevented.'
A bench of Justices L Nageswara Rao and B R Gavai said bodily autonomy and integrity are protected under Article 21 of the Constitution.
He explained, "Children between the age of 12 and 18 years, particularly those in the age group of 15 to 18 years, are very much like adults. Our research within the country also says that almost two-thirds of the deaths below 18 years which occurred due to COVID in India are within this age group. So, this decision was mainly taken to protect the adolescents."
'There is no emergency of a third wave that we are rushing for booster doses.'
The government on Friday said there is no need to panic on the need for an immediate change in the dosage interval of Covishield vaccine, underlining that reducing the time gap requires proper scientific study in the Indian scenario.
According to some experts, there is not much difference in the number of seasonal flu cases and that of COVID-19, even though they stressed that surveillance for newer variants should continue in the off chance of a new lineage of coronavirus catching the country off guard.
'Antibodies remain in the blood for at least seven to nine months.'
Serum Institute of India (SII) and Bharat Biotech have also stopped producing the Covishield and Covaxin vaccines respectively.
Briefing the media in Rome, Goyal said the Leaders adopted the 'Rome Declaration' at the G20 Summit and the communique gives a very strong message under the health section with the countries agreeing that the COVID-19 immunisation is a global public good.
Not enough data has been generated locally to decide on the need for a booster dose of COVID-19 vaccine for those fully inoculated, say experts amid the possibility of a third wave of the viral disease hitting the country between September and October.
Zydus Cadila COVID-19 vaccine for children above 12 years is expected to be available by August as its trials are likely to be completed by July-end, said Dr N K Arora, Chairman, National Technical Advisory Group on Immunisation (NTAGI).
Stressing on the need to protect both lives and livelihoods, he said public health action in India and across the world must be continually guided by evidence from four key questions -- how transmissible is the variant, severity of the disease it causes, how well vaccines and prior SARS-CoV-2 infection protect and how common people perceive risk and follow control measures.
Arora, who is Director of INCLEN Trust, said it is not possible to predict any third wave at this time.
The Delta plus variant of COVID-19 has greater affinity to lung tissues as compared to other strains but it does not mean that it will cause severe disease or is more transmissible, head of coronavirus working group National Technical Advisory Group on Immunisation (NTAGI) Dr N K Arora said.
'he Centre has not issued any mandate, the stand of centre is that it should be 100 per cent but it is not a mandate'
'Someone may have diabetes, but at what level the disease qualifies as a comorbid condition is something a doctor will decide upon and certify accordingly.'
He urged people not to panic and clarified that there was no change in the guidelines for international air travel so far.
Experts emphasise on the need to curb the spread of the novel coronavirus using strategic and pragmatic approaches in villages as well as Tier 2 and Tier 3 cities and towns, which are reporting increased COVID-19 infections and deaths during the ongoing second wave of COVID-19 pandemic.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances